Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (August 2016)
45 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, Aug 23, 2016
Slide 1: Annual Shareholders' Meeting 23 August 2016
Care. Annual Shareholders’ Meeting 23 August 2016
Slide 2: Tony Carter, Chairman
Tony Carter Chairman Fisher Paykel HEALTHCARE
Slide 3: Your Board
Your Board Tony Carter Lewis Gradon Michael Daniell Lindsay Gillanders Geraldine McBride Arthur Morris Donal O’Dwyer Scott St John
Slide 4: Agenda
Agenda Chair’s Address Managing Director and Chief Executive Officer’s Review Financial Statements Resolutions Voting General Questions
Slide 5: Our Business
Our Business PATIENTS TREATED DURING THE YEAR USING OUR MEDICAL POTENTIAL GLOBAL DEVICES MARKET OPPORTUNITY 10M+ US$6B+ CURRENT RANGE OF PRODUCTS, ENGINEERS AND SCIENTISTS ACCESSORIES AND PARTS WORKING IN R&D 500+ 2,700+ SPEND ON R&D NZ$73.3M
Slide 6: Impact of Changing Demographics
Impact of Population age and US Population over age 65 (millions) Changing weight both increasing Demographics • US population 65 100 years+ to grow ~80% 90 80 over next 20 years 70 60 50 40 60% of US healthcare 30 cost is after age 65 years 20 10 0 1970 1990 2010 2030 2050
Slide 7: Developing markets increasing healthcare spending
Impact of Developing markets increasing Changing healthcare spending Demographics – China healthcare expenditure increasing, and expected to exceed US$ 1 trillion by 2020
Slide 8: 2016 Financial Snapshot
2016 Financial Snapshot NZ$ 815m NZ$ 143m 27% 16.7cps RECORD OPERATING RECORD NET PROFIT GROWTH IN NET PROFIT TOTAL DIVIDEND FOR THE REVENUE AFTER TAX AFTER TAX YEAR FULLY IMPUTED
Slide 9: Your Board
Your Board Tony Carter Lewis Gradon Michael Daniell Lindsay Gillanders Geraldine McBride Arthur Morris Donal O’Dwyer Scott St John
Slide 10: Our Team
E (J 2 5 ce) r
Slide 11: Tony Carter, Chairman
r Tony Carter Chairman Fisher & Paykel HEALTHCARE
Slide 12: Lewis Gradon, Managing Director & CEO
Lewis Gradon Managing Director & Chief Executive Officer
Slide 13: Hospital Product Group
Invasive Ventilation Hospital Product Group Non-invasive Ventilation 22% FY16 GROWTH IN Hospital HOSPITAL PRODUCT GROUP REVENUE Respiratory Support Surgical Humidification
Slide 14: Homecare Product Group
Homecare Home Respiratory Product Group Support 21% FY16 GROWTH IN HOMECARE CPAP PRODUCT GROUP Therapy REVENUE
Slide 15: Hospital respiratory support: Optiflow nasal high flow
Growth Hospital respiratory Opportunities support: Optiflow™ nasal high flow CONVENTIONAL NONINVASIVE therapy OXYGEN THERAPY VENTILATION
Slide 16: Optiflow+
Optiflow”+ Fisher Paykel HEALTHCARE
Slide 17: The impact of a new therapy at Lady Cilento Children's Hospital
The impact of a new therapy at Lady Cilento Children’s Hospital
Slide 18: Growth Opportunities: Optiflow and myAIRVO
Growth Hospital respiratory Opportunities support: Optiflow™ Homecare respiratory support: MyAirvo™
Slide 19: myAIRVO 2
~ myAIRVO"2
Slide 20: Growth Opportunities: Surgery
Growth Hospital respiratory Opportunities support: Optiflow™ Homecare respiratory support: MyAirvo™ Surgery
Slide 21: Surgical humidification at the ICENI Centre
Surgical humidification at the ICENI Centre
Slide 22: Growth Opportunities
Growth Hospital respiratory Opportunities support: Optiflow™ Homecare respiratory support: MyAirvo™ Surgery
Slide 23: Research & Development
Research & Development • R&D represents 9% of operating revenue:* NZ$73.3M • Three new product releases * As at 31 March 2016
Slide 24: 950 System
950”System
Slide 25: Nivairo
Nivairo’
Slide 26: Brevida
Brevida”
Slide 27: Global Expansion
© Direct Sales I @ Distributed sales with FPH staff (cj [o) o-]| eit Baer Expansion (© Manufacturing Facilities England = all <. irelane ° = ° France e d 5 O co . ae $d | Japan * Por ' Terao a ’ hs om | ° , China vk ° ® | india | iwi a italy nee, Colombia . m= indona| Australia New 4 Fisher Paykel H
Slide 28: Building on our Auckland Campus
Building 4 on our Auckland Campus
Slide 29: New Campus in Mexico
New Campus in Mexico Fisher Paykel HEALTHCARE
Slide 30: Outlook
Outlook First Half Operating Revenue ~NZ$420 million Net Profit after Tax ~NZ$76 million Full Year Expect at NZD:USD exchange rate of ~0.72 for the balance of the year Operating Revenue ~NZ$880 million Net Profit after Tax ~NZ$165 million* * At the lower end of the guidance range provided in May 201
Slide 31: US$6+ Billion and Growing Market Opportunity
US$6+ Billion and Growing Market Opportunity HOSPITAL HOMECARE Invasive Noninvasive Hospital Surgical Home CPAP Ventilation Ventilation Respiratory Support Humidification Respiratory Support Therapy
Slide 32: Lewis Gradon, Managing Director & CEO
Lewis Gradon Managing Director & Chief Executive Officer
Slide 33: Financial Statements
Financial Statements • Opportunity for shareholders to ask any questions specifically on the financial statements, the auditor’s report or the company’s 2016 annual report. • There will be an opportunity to ask any general questions once all items on the agenda have been considered.
Slide 34: Resolutions
Resolutions • Re-election of Directors • Election of Directors • Auditor’s Remuneration • Issue of Performance Share Rights • Issue of Options
Slide 35: Resolution 1: Re-Election of Director
Resolution 1: That Michael Daniell, Re-Election Of who retires by rotation Director and, being eligible, offers himself for re- election, be re-elected as a director of the Company.
Slide 36: Resolution 2: Re-Election of Director
Resolution 2: That Donal O’Dwyer, Re-Election Of who retires by rotation Director and, being eligible, offers himself for re- election, be re-elected as a director of the Company.
Slide 37: Resolution 3: Election of Director
Resolution 3: That Lewis Gradon, who, Election Of being eligible, offers Director himself for election, be appointed as a director of the Company.
Slide 38: Resolution 4: Election of Director
Resolution 4: That Scott St John, who, Election Of being eligible, offers Director himself for election, be appointed as a director of the Company.
Slide 39: Resolution 5: Auditor's Remuneration
Resolution 5: That the Directors be authorised to fix the fees Auditor’s and expenses of PwC as the Company’s auditor. Remuneration
Slide 40: Resolution 6: Issue of Performance Share Rights
Resolution 6: That approval be given Issue of for the issue of up to Performance 50,000 performance Share Rights share rights under the Fisher & Paykel Healthcare Performance Share Rights Plan to Mr Lewis Gradon, Managing Director and Chief Executive Officer of the Company.
Slide 41: Resolution 7: Issue of Options
Resolution 7: That approval be given Issue of for the issue of up to Options 120,000 options under the Fisher & Paykel Healthcare 2003 Share Option Plan to Mr Lewis Gradon, Managing Director and Chief Executive Officer of the Company.
Slide 42: Voting
Voting • In respect of each resolution, please tick the “for”, “against” or “abstain” box. • Once you have completed your voting, please place your vote in a ballot box. • Please raise your hand if you require a pen. • Results will be announced to NZX and ASX as soon as they are available.
Slide 43: Q&A
Q&A
Slide 44: Proxies
Proxies Resolution For % Against Total votes cast Abstain 1: Re-election of Michael Daniell 357,675,628 99.2% 1,531,265 360,420,070 68,427 2: Re-election of Donal O’Dwyer 351,368,026 97.9% 6,511,617 359,100,316 1,388,181 3: Election of Lewis Gradon 358,138,230 99.4% 992,457 360,370,934 117,563 4: El
Slide 45: Care. Annual Shareholders' Meeting August 2016
Care. Annual Shareholders’ Meeting 23 August 2016
Fisher & Paykel Healthcare — Shareholder Meeting (August 2016) on 6ix